Chiltern Announces Investment in Endpoint


Company News Release

Chiltern International Limited (Chiltern), a global contract research organization (CRO) announced a strategic partnership with endpoint. With this investment, Chiltern becomes a minority shareholder in the company established in April 2009.

Glenn Kerkhof, Chiltern CEO, stated, “Chiltern’s decision to invest in endpoint is representative of our commitment to seek collaborations which connect Chiltern and our clients with leading edge solutions as well as our belief in the technology that endpoint has developed.”

PULSE, endpoint’s configurable system that allows users to design and deploy clinical trial IRT systems, was launched in January of this year. PULSE designs systems that can be accessed via the phone, web, or mobile device.

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.